Erratum: Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma (Blood ( 2017) 130, 5 (2709-2717) DOI: 10.1182/blood-2017-05-780049)

B. Pro, R. Advani, P. Brice

Research output: Contribution to journalComment/debatepeer-review

Abstract

In Table 3 on page 2716 of the 21 December 2017 issue, the second and third column headings are reversed. The second column heading should read “SCT (n ₌ 8),” and the third column heading should read “No SCT (n ₌ 8).” The corrected Table 3 is shown below. (Figure presented). In lines 9 and 10 of the left column on page 2714, “7 patients (88%)” should read “4 patients (50%).” In the next-to-last line of the right column on page 2715, “the majority (7 of 8)” should read “4.” In lines 5 and 6 of the left column on page 2716, “patients who received SCT” should read “patients who did not receive SCT.” The errors have been corrected in the online version of the article.

Original languageEnglish (US)
Pages (from-to)458-459
Number of pages2
JournalBlood
Volume132
Issue number4
DOIs
StatePublished - Jul 26 2018

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Erratum: Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma (Blood ( 2017) 130, 5 (2709-2717) DOI: 10.1182/blood-2017-05-780049)'. Together they form a unique fingerprint.

Cite this